Table 2.
Compound | Species | Transporter | Ft | Reference |
---|---|---|---|---|
Glyburide | Human | BCRP | 0.43 | [91] |
D-luciferin | Mouse | Bcrp | 0.67 | [137] |
Digoxin | Mouse | P-gp | 0.58 | [56] |
Saquinavir | Mouse | P-gp | 0.86 | [56] |
Paclitaxel | Mouse | P-gp | 0.94 | [56] |
L-652,280 | Mouse | P-gp | 0.87 | [57] |
Lopinavir | Mouse | P-gp | 0.5 | [51] |
Norbuprenorphine | Mouse | P-gp | 0 | [61] |
Nitrofurantoin | Mouse | Bcrp | 0.75 | [95] |
Glyburide | Mouse | Bcrp | 0.50 | [96] |
Cyclosporine | Rat | P-gp | 0.41 | [138] |
Tenofovir | Rat | Bcrp | 0.33 | [92] |
Ft values of drugs in mice were estimated using Equation 3 with data in P-gp or Bcrp KO and WT mice. Ft values of drugs in humans or rats were estimated using Equation 4 with placental perfusion data in the presence and absence of an inhibitor. In all the calculations, total plasma or perfusate concentrations or AUCs were used, assuming that that the plasma protein binding of drugs remains the same across the placental barrier.